BDBM283367 N-((3-chloro-1H-pyrrolo[2,3-b]pyridin-5- yl)methyl)-2-((3-methyl-8- (methylsulfonyl)quinolin-6- yl)methyl)isonicotinamide::US10023557, Example 19::US10266515, Example 19::US10308637, Example 19::US11021463, Example 19::US9611252, Example 19

SMILES Cc1cnc2c(cc(Cc3cc(ccn3)C(=O)NCc3cnc4[nH]cc(Cl)c4c3)cc2c1)S(C)(=O)=O

InChI Key InChIKey=IIORZUFKRKFNHD-UHFFFAOYSA-N

Data  5 IC50  2 EC50

  Tab Delimited (TSV)   2D SDfile   Computed 3D by Vconf -m prep SDfile
Find this compound or compounds like it in BindingDB:
   Substructure
Similarity at least:  must be >=0.5
Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 7 hits for monomerid = 283367   

TargetPlasma kallikrein(Homo sapiens (Human))
Lifesci Pharmaceuticals

US Patent
LigandPNGBDBM283367(N-((3-chloro-1H-pyrrolo[2,3-b]pyridin-5- yl)methyl...)
Affinity DataIC50: <100nMpH: 7.5Assay Description:A 10 mM solution of the test compound was made in DMSO. This solution was serially diluted 1:5 in DMSO to yield 2000, 400, 80, 16, 3.2, 0.64, 0.128, ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
Lifesci Pharmaceuticals

US Patent
LigandPNGBDBM283367(N-((3-chloro-1H-pyrrolo[2,3-b]pyridin-5- yl)methyl...)
Affinity DataIC50: <100nMAssay Description:The ability of the compounds disclosed herein to inhibit human plasma kallikrein activity was quantified according to the procedures below.A 10 mM so...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetMitogen-activated protein kinase kinase kinase kinase 1(Homo sapiens (Human))
Lifesci Pharmaceuticals

US Patent
LigandPNGBDBM283367(N-((3-chloro-1H-pyrrolo[2,3-b]pyridin-5- yl)methyl...)
Affinity DataIC50: <100nMAssay Description:A 10 mM solution of the test compound was made in DMSO. This solution was serially diluted 1:5 in DMSO to yield 2000, 400, 80, 16, 3.2, 0.64, 0.128, ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
Lifesci Pharmaceuticals

US Patent
LigandPNGBDBM283367(N-((3-chloro-1H-pyrrolo[2,3-b]pyridin-5- yl)methyl...)
Affinity DataEC50: <100nMAssay Description:Materials:Plasma kallikrein inhibitor C1NH (Athens Research & Technology, Cat #16-16-031509); Ellagic acid (Sigma, E2250); Substrate Z-FR-2-AMC (GL B...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
Lifesci Pharmaceuticals

US Patent
LigandPNGBDBM283367(N-((3-chloro-1H-pyrrolo[2,3-b]pyridin-5- yl)methyl...)
Affinity DataEC50: <100nMAssay Description:Human plasma is thawed on ice and centrifuged for 15 min at 4° C. to remove platelets. A 1 mM stock solution of ellagic acid is diluted to 8 μM ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
Lifesci Pharmaceuticals

US Patent
LigandPNGBDBM283367(N-((3-chloro-1H-pyrrolo[2,3-b]pyridin-5- yl)methyl...)
Affinity DataIC50: <100nMAssay Description:A 10 mM solution of the test compound was made in DMSO. This solution was serially diluted 1:5 in DMSO to yield 2000, 400, 80, 16, 3.2, 0.64, 0.128, ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
Lifesci Pharmaceuticals

US Patent
LigandPNGBDBM283367(N-((3-chloro-1H-pyrrolo[2,3-b]pyridin-5- yl)methyl...)
Affinity DataIC50: <100nMAssay Description:A 10 mM solution of the test compound was made in DMSO. This solution was serially diluted 1:5 in DMSO to yield 2000, 400, 80, 16, 3.2, 0.64, 0.128, ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent